Friday, December 16, 2011

Drug Discovery@nature.com 16 December 2011

Drug Discovery

TABLE OF CONTENTS

16 December 2011

News
Analysis
Research Highlights
Research & Reviews
Careers


Nature Reviews Drug Discovery is on Twitter

Advertisement
Scientific Reports – Call for papers

Publishing made easy! Entirely open access with papers accepted on technical merit, the community evaluates the importance of papers post-peer review. Scientific Reports exists to facilitate the rapid peer review and publication of research that is of interest to specialists within any given field in the natural sciences.

Submit now!
 

News

Top

Class of once-weekly diabetes drugs poised for approval
doi:10.1038/nm1211-1528b
A decision is expected from the US Food and Drug Administration by 28 January on the regulatory approval of the once-weekly injectable diabetes medication, Bydureon, made by Amylin Pharmaceuticals and Eli Lilly.
Full Text

Interest groups jostle to influence PDUFA V
doi:10.1038/nbt1211-1062
The contents of the finalized package of formal recommendations for the Prescription Drug User Fee Act V reflect many rounds of negotiations involving the US Food and Drug Administration, industry, medical groups, patient and consumer representatives and the general public.
Full Text

Industry continues dabbling with open innovation models
doi:10.1038/nbt1211-1063a
Several open innovation initiatives have been launched in a bid to share intellectual property and thereby speed up drug discovery.
Full Text

Four-in-one HIV pill may be exception among combination drugs
doi:10.1038/nm1211-1528a
If approved, Gilead’s four-in-one HIV 'Quad' pill promises the same virus-controlling ability as the four drugs separately but should be easier to use for people with the infection.
Full Text

Analysis

Top

Big MAC attack in osteoarthritis
doi:10.1038/scibx.2011.1311
An international team has shown that inhibiting the complement system could help slow disease progression in osteoarthritis, thus handing a potentially disease-modifying strategy to companies developing complement 5 inhibitors.
Full Text

Crizotinib
doi:10.1038/nrd3600
In August 2011, crizotinib (Xalkori; Pfizer), a small-molecule kinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma kinase-positive, as detected by an FDA-approved test.
Full Text

Personalized medicine in oncology: next generation
doi:10.1038/nrd3603
This article outlines the challenges, such as clinical trial design, biomarker selection, accurately forecasting sales potential and pricing, that face pharmaceutical companies in the development of targeted drugs.
Full Text

Research Highlights

Top

Analgesia: Unravelling epigenetic mechanisms of chronic pain
doi:10.1038/nrd3606
Results from a new study suggest that histone deacetylase inhibitors could be used as analgesics to target the development of chronic pain.
Full Text

Medical devices: A protective stent coating
doi:10.1038/nrd3604
Researchers have shown that coating stents with cathelicidin, an antimicrobial peptide released from neutrophils, could represent a novel strategy for preventing restenosis.
Full Text

Therapeutics: Another tool in the BCR–ABL kit?
doi:10.1038/nrc3173
Inhibiting an interaction between the SH2 and kinase domains of BCR–ABL, which facilitates kinase activation, prevents leukaemogenesis in mice and can restore sensitivity to tyrosine kinase inhibitors.
Full Text

Research & Reviews

Top

Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets
doi:10.1038/nrd3599
This article summarizes the evidence for the participation of CCN matricellular proteins in disease pathologies, explores their potential as diagnostic markers and therapeutic targets, and outlines various strategies to target these proteins.
Full Text

MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
doi:10.1038/nrc3166
In addition to highlighting the use of mouse models to understand the roles of miRNAs in cancer and metastasis, this article reviews the recent literature regarding the transition of these master regulators into clinical settings both as direct cancer therapeutics and as tools to sensitize tumours to traditional chemotherapeutics.
Full Text

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
doi:10.1038/nm.2579
Preliminary evidence indicates that the drug dexpramipexole may have clinical activity in a small placebo-controlled trial in patients with the neurodegenerative disease amyotrophic lateral sclerosis.
Full Text

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
doi:10.1038/nature10662
Researchers have identified a novel mechanism of acquired resistance to RAF inhibitors in patients: expression of splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner.
Full Text

Drug Discovery
JOBS of the week
Elings Prize Fellowships in Experimental Science
University of California
Research Fellow
Physicians Committee for Responsible Medicine
Research Associate
University of Cambridge
Research Associate
Imperial College London
Senior Medical Writer
Vertex Pharmaceuticals
More Science jobs from
Drug Discovery
EVENT
Drug discovery: a job too complex for academia or industry alone?
05.-06.01.12
Oxford, UK
More science events from

Careers

Top

Career snapshots archive
Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field.
Full Text

Top
Advertisement
Nature Reviews Genetics
POSTER - Tools for studying and using small RNAs: from pathways to functions to therapies
Authors: Kenneth Chang and Gregory J. Hannon
November 2011

Access the Poster FREE online!
www.nature.com/nrg/posters/small-rna

COMING SOON: RNA interference animation

Produced with support from
Thermo Scientific
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: